NASDAQ:ONTXOnconova Therapeutics Stock Price, Forecast & News

Onconova Therapeutics' stock was trading at $0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ONTX stock has increased by 8.3% and is now trading at $0.39. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Onconova Therapeutics.

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Onconova Therapeutics.

Onconova Therapeutics Inc (NASDAQ:ONTX) released its quarterly earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The biopharmaceutical company earned $0.05 million during the quarter, compared to analysts' expectations of $0.10 million. Onconova Therapeutics had a negative net margin of 876.56% and a negative return on equity of 340.18%. View Onconova Therapeutics' earnings history.

Shares of Onconova Therapeutics reverse split on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

3 analysts have issued 12 month price objectives for Onconova Therapeutics' shares. Their forecasts range from $1.25 to $1.30. On average, they expect Onconova Therapeutics' stock price to reach $1.28 in the next twelve months. This suggests a possible upside of 226.9% from the stock's current price. View analysts' price targets for Onconova Therapeutics.

News stories about ONTX stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Onconova Therapeutics earned a news impact score of -1.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutOnconova Therapeutics.

Some companies that are related to Onconova Therapeutics include Aduro BioTech (ADRO), Abeona Therapeutics (ABEO), Northwest Biotherapeutics (NWBO), Spero Therapeutics (SPRO), REDHILL BIOPHAR/S (RDHL), Agile Therapeutics (AGRX), Fortress Biotech (FBIO), Affimed (AFMD), MediciNova (MNOV), Hookipa Pharma (HOOK), XOMA (XOMA), Chimerix (CMRX), OptiNose (OPTN), Five Prime Therapeutics (FPRX) and Iterum Therapeutics (NRBO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Opko Health (OPK), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Crispr Therapeutics (CRSP), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE) and Agile Therapeutics (AGRX).

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Onconova Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (0.10%) and Quilter Plc (0.10%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Jerome Groopman, Mark Patrick Guerin, Michael B Hoffman, Steven M Fruchtman and Tyndall Capital Partners L P. View institutional ownership trends for Onconova Therapeutics.

ONTX stock was bought by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., and Quilter Plc. Company insiders that have bought Onconova Therapeutics stock in the last two years include Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Jerome Groopman, Mark Patrick Guerin, and Steven M Fruchtman. View insider buying and selling activity for Onconova Therapeutics.

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ONTX stock can currently be purchased for approximately $0.39.

Onconova Therapeutics has a market capitalization of $65.78 million and generates $2.18 million in revenue each year. The biopharmaceutical company earns $-21,500,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

The official website for Onconova Therapeutics is www.onconova.com.

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]